Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study of Unesbulin (PTC596) in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma

NCT03761095 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT03761095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03761095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study of Unesbulin (PTC596) in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma
Lead sponsor
PTC Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 13, 2019
Completion date
February 5, 2024
Enrollment
41 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma